Artiva director granted 13,750 stock options

Artiva Biotherapeutics disclosed a new stock option grant to a director with 13,750 options vesting by the 2027 annual meeting.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of 13,750 stock options on September 8, 2026. The options have an exercise price of $10.88 per share, expire on September 7, 2036, and vest in full on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 13,750 shares

Grant/Award 1 txn

Insider MOORE ALISON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	13,750	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Stock options granted: 13,750 options Exercise price: $10.88 per share Expiration date: September 7, 2036 +2 more

5 metrics

Stock options granted 13,750 options Director stock option grant on September 8, 2026

Exercise price $10.88 per share Exercise price of director stock options granted September 8, 2026

Expiration date September 7, 2036 Expiration of the director stock option grant

Vesting date trigger Earlier of September 8, 2027 or 2027 annual meeting Full vesting condition for the 13,750 options

Post-transaction options held 13,750 options Total derivative securities beneficially owned after this grant

Key Terms

Director Stock Option (Right to Buy), exercise price, annual stockholder meeting, vest in full

4 terms

Director Stock Option (Right to Buy) financial

"security titled "Director Stock Option (Right to Buy)""

exercise price financial

"conversion or exercise price of $10.8800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual stockholder meeting financial

"earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

vest in full financial

"shares subject to the option will vest in full on the earlier of"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artiva Biotherapeutics (ARTV) report in this Form 4 filing?

Artiva Biotherapeutics reported that director Alison Moore received a grant of 13,750 stock options on September 8, 2026, to purchase the company’s common stock, with specified vesting and expiration terms.

What are the key terms of the new stock options reported for ARTV?

The filing shows 13,750 stock options with an exercise price of $10.88 per share, expiring on September 7, 2036. These options relate to Artiva Biotherapeutics’ common stock and were acquired as a director compensation grant.

When do Alison Moore’s ARTV stock options vest?

According to the Form 4, the 13,750 options vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, making vesting contingent on whichever of those events occurs first.

How many ARTV options does Alison Moore hold after this transaction?

After the reported grant, Alison Moore holds 13,750 stock options directly. The Form 4 lists this amount as the total derivative securities beneficially owned following the transaction for this award.

Is the ARTV director option grant under a Rule 10b5-1 trading plan?

No. The document-level checkbox for Rule 10b5-1 is not selected, indicating the September 8, 2026 stock option grant to director Alison Moore was not reported as made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:55 PM EDT Accepted by SEC EDGAR 09/08/2026 - 05:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOORE ALISON

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.88	09/08/2026		A		13,750		(1)	09/07/2036	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)